Tumor regressions were seen in nearly all (RET-mutated) patients receiving selpercatinib (LIBRETTO-001 trial), regardless of the kind of RET mutation or whether the participant had or had not received previous TKI treatment with cabozantinib, vandetanib, or both. This evidence concerns the gene RET and neoplasm.